ASTX727 (decitabine/cedazuridine)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for ASTX727 (decitabine/cedazuridine), covering 2026-04-13 to 2026-04-14. Get the full timeline:
Most recent: Clinical Trial Update: A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) [Phase 1, Phase 2]